Cargando…

Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis

BACKGROUND: The impact of sacubitril–valsartan on heart failure (HF) patients with preserved ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the clinical advantages and safety of sacubitril–valsartan in patients with HFpEF. METHODS: PubMed and Web of Science...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basile, Christian, Paolillo, Stefania, Gargiulo, Paola, Marzano, Federica, Asile, Gaetano, Parlati, Antonio Luca Maria, Chirico, Alfonsina, Nardi, Ermanno, Buonocore, Davide, Colella, Angela, Perrone-Filardi, Pasquale
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Research articles: Heart Failure
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794138/ https://www.ncbi.nlm.nih.gov/pubmed/36574300 http://dx.doi.org/10.2459/JCM.0000000000001411

Ejemplares similares

Cardiorenal syndrome: Pathophysiology as a key to the therapeutic approach in an under‐diagnosed disease
por: Prastaro, Maria, et al.
Publicado: (2022)

MicroRNAs: diagnostic, prognostic and therapeutic role in heart failure—a review
por: Gargiulo, Paola, et al.
Publicado: (2022)

Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Benini, Annachiara, et al.
Publicado: (2022)

Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study
por: Ganesananthan, Sashiananthan, et al.
Publicado: (2020)

Depression in Heart Failure with Reduced Ejection Fraction, an Undervalued Comorbidity: An Up-To-Date Review
por: Basile, Christian, et al.
Publicado: (2023)

PREDICTORS OF LIKELIHOOD OF TAKING SACUBITRIL-VALSARTAN AND A HYPOTHETICAL MEDICATION FOR COVID-19
por: Thomson, Mary Catherine, et al.
Publicado: (2021)

Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis
por: Nielsen, Emil Eik, et al.
Publicado: (2020)

(123)I-MIBG imaging in heart failure: impact of comorbidities on cardiac sympathetic innervation
por: Gargiulo, Paola, et al.
Publicado: (2022)

Continuous infusion of furosemide versus intermittent boluses in acute decompensated heart failure: Effect on thoracic fluid content
por: Ragab, Dalia, et al.
Publicado: (2018)

Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis
por: Putri, Desak Ketut Sekar Cempaka, et al.
Publicado: (2023)

Sacubitril/valsartan in the treatment of systemic right ventricular failure
por: Zandstra, Tjitske E, et al.
Publicado: (2021)

Renal protection in chronic heart failure: focus on sacubitril/valsartan
por: Pontremoli, Roberto, et al.
Publicado: (2021)

Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure
por: Njoroge, Joyce N., et al.
Publicado: (2021)

Polypharmacy and Clinical Outcomes in Hospitalized Patients With Acute Decompensated Heart Failure
por: Ozasa, Neiko, et al.
Publicado: (2023)

Prognosis and risk stratification in patients with decompensated heart failure receiving inotropic therapy
por: Gomes, Clara, et al.
Publicado: (2018)

Inferior vena cava diameter and risk of acute decompensated heart failure rehospitalisations
por: Sampath-Kumar, Revathy, et al.
Publicado: (2023)

Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction
por: Yoshihisa, Akiomi, et al.
Publicado: (2020)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
por: Carballo, David, et al.
Publicado: (2020)

Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration
por: Mapelli, Massimo, et al.
Publicado: (2023)

Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction
por: Guazzi, Marco, et al.
Publicado: (2021)

Ischaemia change with revascularisation versus medical therapy in reduced ejection fraction
por: Mentz, Robert J, et al.
Publicado: (2015)

Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure
por: Gijsberts, Crystel M, et al.
Publicado: (2016)

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition
por: Margonato, Davide, et al.
Publicado: (2020)

Specialist intervention is associated with improved patient outcomes in patients with decompensated heart failure: evaluation of the impact of a multidisciplinary inpatient heart failure team
por: Masters, Jayne, et al.
Publicado: (2017)

In-hospital electrical muscle stimulation for patients early after heart failure decompensation: results from a prospective randomised controlled pilot trial
por: Poltavskaya, Maria, et al.
Publicado: (2022)

Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Beale, Anna L, et al.
Publicado: (2019)

Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction
por: Salah, Khibar, et al.
Publicado: (2019)

Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction
por: Son, Mi Kyoung, et al.
Publicado: (2020)

Diastolic index as a short-term prognostic factor in heart failure with preserved ejection fraction
por: Hoshida, Shiro, et al.
Publicado: (2020)

Association of early versus delayed normalisation of left ventricular ejection fraction with mortality in ischemic cardiomyopathy
por: Schiffer, Walter B, et al.
Publicado: (2021)

Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review
por: Zheng, Sean L, et al.
Publicado: (2016)

Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
por: Verbrugge, Frederik H, et al.
Publicado: (2021)

Implantation of a vagus nerve stimulator for patients with heart failure with reduced ejection fraction: An educational video
por: Al Rameni, Dina, et al.
Publicado: (2022)

Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction
por: van Essen, Bart J., et al.
Publicado: (2022)

Superiority of proatrial natriuretic peptide in the prognostic power in patients with acute decompensated heart failure on hospital admission: comparison with B-type natriuretic peptide and other natriuretic peptide forms
por: Takashio, Seiji, et al.
Publicado: (2019)

Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study
por: Hage, Camilla, et al.
Publicado: (2015)

Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Zheng, Sean Lee, et al.
Publicado: (2018)

Baseline characteristics of patients with heart failure and preserved ejection fraction at admission with acute heart failure in Saudi Arabia
por: Abohammar, Samah, et al.
Publicado: (2017)

Association between implanted cardioverter-defibrillators and mortality for patients with left ventricular ejection fraction between 30% and 35%
por: Wasfy, Jason H, et al.
Publicado: (2023)

Development of algorithms for determining heart failure with reduced and preserved ejection fraction using nationwide electronic healthcare records in the UK
por: Sundaram, Varun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1ggb6ego4offpc5der8uoi9v5t